What is Leerink Partnrs’ Estimate for NAMS Q4 Earnings?

NewAmsterdam Pharma (NASDAQ:NAMS) – Analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for shares of NewAmsterdam Pharma in a research note issued on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s FY2028 earnings at $0.42 EPS.

A number of other analysts have also recently weighed in on NAMS. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $36.20.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $25.46 on Thursday. The company has a 50 day moving average of $21.16 and a two-hundred day moving average of $18.90. NewAmsterdam Pharma has a twelve month low of $10.29 and a twelve month high of $27.29.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the sale, the insider now owns 11,150,461 shares of the company’s stock, valued at approximately $283,110,204.79. The trade was a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 252,814 shares of company stock valued at $5,970,327. 19.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently added to or reduced their stakes in NAMS. Banque Cantonale Vaudoise acquired a new position in shares of NewAmsterdam Pharma in the 2nd quarter valued at about $38,000. Quarry LP raised its position in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after acquiring an additional 6,247 shares in the last quarter. Barclays PLC lifted its holdings in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares during the period. Bellevue Group AG purchased a new stake in NewAmsterdam Pharma in the 3rd quarter worth approximately $128,000. Finally, XTX Topco Ltd acquired a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $187,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.